25 August 2023
Authorisation application submitted for coronavirus vaccine Nuvaxovid XBB.1.5
Future Health Pharma GmbH submitted the authorisation application on behalf of Novavax. The application concerns the updated Nuvaxovid monovalent COVID-19 vaccine from Novavax. The protein-based vaccine contains a non-infectious component from the surface of SaRS-CoV-2 Omicron subvariant XBB.1.5., which triggers a protective immune response when the body’s immune cells come into contact with it. Swissmedic is examining the application.
For more information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Swissmedic: Haemovigilance Annual Report 2025
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
Swissmedic: Revision of the Guidance document Authorisation Biosimilar